Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | AOC1 | P19801 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 2/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12319209 | 0.79 | NOS3 (0.38) | KDM4ENOS3NOS1NOS2CCR1 | |
| SCHEMBL15142288 | 0.78 | LMNA (0.42) | LMNAAOC3AOC1NOS3NOS1 | |
| SCHEMBL9970101 | 0.78 | LMNA (0.50) | LMNAAOC3KDM4EAOC1LOX | |
| SCHEMBL14682728 | 0.78 | LMNA (0.65) | LMNAAOC3KDM4EAOC1NOS3 | |
| SCHEMBL9970098 | 0.75 | LMNA (0.71) | LMNAAOC3KDM4ELOXALDH1A1 | |
| Ethylenediamine SCHEMBL6295958 | 0.74 | CCR1 (0.38) | LMNAKDM4ENOS3NOS1NOS2 | |
| SCHEMBL17229270 | 0.74 | KDM5A (0.32) | CCR1CCR5CCR8 | |
| SCHEMBL9970114 | 0.71 | DPP4 (0.43) | LMNAAOC3 | |
| SCHEMBL3671331 | 0.70 | NOS3 (0.44) | KDM4ENOS3NOS1NOS2CCR1 | |
| SCHEMBL22972190 | 0.70 | AOC3 (0.48) | LMNAAOC3AOC1LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003101-A | A kind of Ah pa is for Buddhist nun's intermediate and preparation method thereof | 苏州富士莱医药股份有限公司 | 2019-07-12 | — | — | CN | disclosed |
| US-20180153827-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | MTI BIOTECH, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20140256774-A1 | METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | VANDERBILT UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-8822542-B2 | Isoketal scavengers and mitigation of disorders involving oxidative injury | VANDERBILT UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | VANDERBILT UNIVERSITY | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256774-A1 | METHODS FOR TREATING INFLAMMATION AND HYPERTENSION WITH GAMMA-KETOALDEHYDE SKAVENGERS | AKR1B1, NFKBIA, PTGS2 | LMNA 1062/4885AOC3 706/4885KDM4E 607/4885 |
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | PDXK, KYNU, FN3K | LMNA 2014/4885AOC3 501/4885KDM4E 1534/4885 |
| US-20180153827-A1 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | CPT1A, AKR7A2, FABP1 | LMNA 703/4885AOC3 480/4885KDM4E 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.